1 |
Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997;4:415-22.
|
2 |
Kim KH, Yu J, Nahm MH. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol 2003;10:616-21.
|
3 |
Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4.
DOI
|
4 |
Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007;25:2518-27.
DOI
ScienceOn
|
5 |
Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 Suppl):S66-S76.
DOI
|
6 |
Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009;199:776-85.
DOI
ScienceOn
|
7 |
Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010;28:4249-59.
DOI
ScienceOn
|
8 |
World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. Proposed replacement of TRS 927, Annex 2. 2009. Available from: http://www.who.int/biologicals/areas/vaccines/pneumo/Pneumo_final_23APRIL_2010.pdf
|
9 |
Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006;13:356-60.
DOI
ScienceOn
|
10 |
Park SE, Lee H, Lim SY, Kim KH. Immunogenicity of 7-valent pneumococcal conjugate vaccine related to booster immunization in Korean children. Korean J Pediatr 2008;51:622-8.
DOI
ScienceOn
|
11 |
Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003;10:514-9.
|
12 |
Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006;13:1004-9.
DOI
ScienceOn
|
13 |
Wang D, Burton RL, Nahm MH, Soong SJ. A four-parameter logistic model for estimating titers of functional multiplexed pneumococcal opsonophagocytic killing assay. J Biopharm Stat 2008;18:307-25.
DOI
ScienceOn
|
14 |
Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006;13:165-9.
DOI
ScienceOn
|
15 |
Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468-72.
DOI
ScienceOn
|
16 |
Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8.
|
17 |
Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee HJ, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-81.
DOI
|
18 |
Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdottir I. Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun 2003;71:2956-9.
DOI
ScienceOn
|
19 |
Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-502.
DOI
ScienceOn
|
20 |
Lee HJ, Lim SY, Kim KH. Immune response to serotype 19A induced by serotype 19F in pneumococcal protein conjugate vaccine. Clin Microbiol Infect 2007;13:S294.
|
21 |
Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009;16:376-81.
DOI
ScienceOn
|
22 |
American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. Redbook: 2009 Report of the Committee in Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:524-35.
|
23 |
Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001;8:266-72.
|